healthcare investing Archives

Comic-style illustration of Michael J. Fox pointing toward Parkinson’s research and clinical trial displays, surrounded by scientists, patients and investors, with upward arrows symbolizing progress and investor optimism.

The Michael J. Fox Foundation Is Building Parkinson’s Next Chapter. Investors Have Reason to Pay Attention. -( $ABBV $IBB $SER $XBI )

by John F. Heerdink, Jr. 2 days ago 181Views 0Likes

Better biomarkers, new FDA approvals and an emerging delivery pipeline strengthen the case for Parkinson’s innovation, with AbbVie and Serina Therapeutics offering distinct investment angles. The most compelling Parkinson’s investment story does not begin with a stock chart. It begins with a…

Zenflow’s $52 Million Raise Gives Its BPH Breakthrough Commercial Muscle -( $HSBC $TRIN )

by John F. Heerdink, Jr. 3 days ago 135Views 0Likes

An exclusive U.S. distribution agreement with Cook Medical adds an established sales channel to Zenflow’s FDA-approved Spring System, and strengthens the case for a new approach to enlarged-prostate treatment. Zenflow has reached a consequential stage in the medical-device business: its technology is…

Trading-floor monitor displaying McKesson and Option Care Health logos, a $5.8 billion deal headline and an upward arrow representing home infusion growth.

McKesson’s $5.8 Billion Option Care Deal Puts Home Infusion in Wall Street’s Spotlight -( $MCK $OPCH )

by John F. Heerdink, Jr. 4 days ago 443Views 0Likes

The proposed acquisition offers Option Care Health shareholders a substantial cash premium, and gives McKesson a strategic foothold in delivering complex therapies closer to patients. McKesson Corporation (NYSE: MCK) and private investment firm Clayton, Dubilier & Rice are making a $5.8 billion…

Iovance Biotherapeutics revenue guidance display in a modern trading-floor setting, highlighting rising Amtagvi demand, a Goldman Sachs Buy rating, and NASDAQ market screens.

Iovance Biotherapeutics Raises 2026 Revenue Guidance as Amtagvi Demand Accelerates & Goldman Resumes Coverage – ( $GS $IOVA $XBI $IBB )

by John F. Heerdink, Jr. September 30, 2026 383Views 0Likes

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) delivered the sort of update growth investors prefer: higher guidance, record revenue, expanding treatment access, and a more visible route toward operating leverage. Shares climbed sharply after the company lifted its 2026 revenue outlook, suggesting Wall Street is…

Investor-focused healthcare graphic showing a laboratory scene, a clinician holding a drug-delivery device, a glowing brain illustration, molecular imagery and a city skyline. The image highlights AbbVie Inc. (NYSE: ABBV) receiving FDA approval for JUVMO (tavapadon) for Parkinson’s disease and positions Serina Therapeutics Inc. (NYSE American: SER) and its SER-252 program as a potential next-generation therapy opportunity in advanced Parkinson’s disease.

AbbVie’s JUVMO Approval Puts Parkinson’s Innovation Back in Motion And Serina Therapeutics Has a Timely Opening -( $ABBV $AMRX $SER $SUPN $IBB $XBI )

by John F. Heerdink, Jr. September 29, 2026 418Views 0Likes

AbbVie Inc. (NYSE: ABBV) has secured (Sept. 28) FDA approval for JUVMO™ (tavapadon), a new once-daily Parkinson’s therapy, adding an important fresh option to a market long defined by the delicate art of managing motor symptoms, “OFF” time, dyskinesia and medication burden. For Serina…

Illustration of a brain transitioning from a cracked, burdened form to a vibrant neural network, symbolizing advanced Parkinson’s disease treatment innovation, continuous dopamine therapy and improved drug delivery.

Serina Therapeutics Advances SER-252 in Advanced Parkinson’s Disease as Continuous Therapy Market Expands -( $ABBV $SER )

by John F. Heerdink, Jr. September 25, 2026 460Views 0Likes

SER-252 enters Cohort 2 with blinded early observations that support the central premise: sustained delivery of a proven Parkinson’s medicine may be far more valuable when it asks less of patients and caregivers. In biotechnology, there are moonshots, and then there are…

Promotional graphic for Tribe Public’s CEO presentation and Q&A webinar, “A New Approach to Advanced Parkinson’s Disease: Exploring SER-252’s Clinical Progress,” featuring Serina Therapeutics CEO Steven Ledger; September 24, 2026, at 8:30 a.m. PT / 11:30 a.m. ET.

Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24

by John F. Heerdink, Jr. September 23, 2026 181Views 0Likes

Parkinson’s disease is one of medicine’s most stubborn commercial and scientific frontiers, and Serina Therapeutics, Inc. (NYSE American: SER) is positioning its lead program, SER-252, squarely in the middle of that opportunity. The clinical-stage biotechnology company has opened registration for a Tribe Public CEO…

Comic-book-style Wall Street illustration featuring a charging bull superhero, symbols of insider conviction and high-speed OLED technology, virtual-care clinicians, and a scientist representing Parkinson’s disease research, beneath the headline “Wall Street’s Bullish New Menu.”

Wall Street’s Bullish New Menu: Insider Conviction, OLED Speed, Virtual Care and a Parkinson’s Catalyst -( $AMWL $GME $LPL $PFE $SER $XBI )

by John F. Heerdink, Jr. September 22, 2026 268Views 0Likes

The market’s most compelling bullish narratives rarely arrive wearing the same uniform. This week, they span a CEO buying millions of dollars of his own stock, an OLED display running at a downright impolite 720Hz, a telehealth company pursuing large institutional accounts,…

Tribe Public CEO Presentation and Q&A webinar graphic featuring Serina Therapeutics CEO Steven Ledger, NYSE: SER, promoting “A New Approach to Advanced Parkinson’s Disease: Exploring SER-252’s Clinical Progress,” with a global network map, molecular imagery, and Register Now call to action.

Serina Therapeutics Brings a Fresh Dose of Momentum to Advanced Parkinson’s Care -( $SER $PFE $XBI )

by John F. Heerdink, Jr. September 21, 2026 350Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) is approaching a consequential clinical milestone with SER-252, its long-acting POZ-apomorphine candidate for advanced Parkinson’s disease, now advancing into Cohort 2 of a registrational Phase 1b study. For many, the appeal is not simply that Serina is pursuing…

Dartboard with three darts clustered near the bullseye and “$150M” displayed at the center, symbolizing Beta Bionics’ targeted $150 million public offering.

Beta Bionics Raises $150 Million as FDA-Cleared Mint Patch Pump Sets Up 2027 Growth Story -( $BBNX )

by John F. Heerdink, Jr. September 17, 2026 274Views 0Likes

Beta Bionics, Inc. (NASDAQ: BBNX) has priced a $150 million public offering this week just as its product story is acquiring more commercial torque: FDA clearance for the Mint™ patch pump, a planned U.S. launch in the first quarter of 2027, and a…

Tag: healthcare investing

The Michael J. Fox Foundation Is Building Parkinson’s Next Chapter. Investors Have Reason to Pay Attention. -( $ABBV $IBB $SER $XBI )

Zenflow’s $52 Million Raise Gives Its BPH Breakthrough Commercial Muscle -( $HSBC $TRIN )

McKesson’s $5.8 Billion Option Care Deal Puts Home Infusion in Wall Street’s Spotlight -( $MCK $OPCH )

Iovance Biotherapeutics Raises 2026 Revenue Guidance as Amtagvi Demand Accelerates & Goldman Resumes Coverage – ( $GS $IOVA $XBI $IBB )

AbbVie’s JUVMO Approval Puts Parkinson’s Innovation Back in Motion And Serina Therapeutics Has a Timely Opening -( $ABBV $AMRX $SER $SUPN $IBB $XBI )

Serina Therapeutics Advances SER-252 in Advanced Parkinson’s Disease as Continuous Therapy Market Expands -( $ABBV $SER )

Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24

Wall Street’s Bullish New Menu: Insider Conviction, OLED Speed, Virtual Care and a Parkinson’s Catalyst -( $AMWL $GME $LPL $PFE $SER $XBI )

Serina Therapeutics Brings a Fresh Dose of Momentum to Advanced Parkinson’s Care -( $SER $PFE $XBI )

Beta Bionics Raises $150 Million as FDA-Cleared Mint Patch Pump Sets Up 2027 Growth Story -( $BBNX )

Your Guide To Staying Informed In The Markets